What Syndax Pharmaceuticals Holders Got Wrong Before The Slide

If you had read the bullish and bearish Syndax Pharmaceuticals writeups and decided to sit it out, the result might feel very different today. Holding Syndax Pharmaceuticals from the start of the year would have meant a 37.1% loss, including dividends. The move is now history. The useful question is what a reader could have examined back on 1 January 2026, before the approvals, data readouts and price swings arrived.

Syndax Pharmaceuticals has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.

The Argument You Would Have Been Weighing Up On Syndax Pharmaceuticals

The shares cost US$21.01 and investors in Syndax Pharmaceuticals had to choose between two very different stories.

The bullish view pointed to a Fair Value of US$36.55, an implied upside based on expectations of 97.8% annual revenue growth and a move to a 7.2% profit margin over three years.

The cautious side worked off a Fair Value of US$19, tied to assumptions of 79.7% yearly sales growth, and highlighted heavy dependence on Revuforj and Niktimvo as a key concentration risk.

What The 2026 Evidence Actually Tested For Syndax Pharmaceuticals

The clearest new data came from Syndax Pharmaceuticals reporting Q2 2026 revenue of US$72.8 million, up from US$38.0 million a year earlier. The loss narrowed to US$49.4 million and net margin improved to a 67.8% loss from a 189.3% loss. That shift supported the focus on scaling Revuforj and Niktimvo, yet profitability remained unproven, so the results had both positive and negative aspects.

The decision in hindsight depended on how quickly operating losses might shrink. For a different biotech, you would test that same assumption by tracking revenue per quarter alongside the direction of net margin, rather than looking only at headline growth forecasts.

What Syndax Pharmaceuticals' Drop Has Left In The Price

Syndax Pharmaceuticals now trades at US$13.4, after falling 37.1% from the start of the year. The selected Narrative sets a Fair Value above that price and anchors its case on how far Revuforj and Niktimvo can carry the business.

For that higher figure to prove reasonable, a buyer today would need confidence that these two drugs can scale enough to absorb high R&D and SG&A spending.

"The main thing that has to go right is that Revuforj and Niktimvo continue to scale across additional AML, GVHD, and fibrosis indications, while high R&D and SG&A spending near US$400 million in 2026 eventually converts into sustainable profitability rather than ongoing losses."

One Narrative disagrees with today's price. → See where this Narrative says Syndax Pharmaceuticals should trade

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 36% below our estimate - converts a record advisory pipeline and senior hires into higher fee transactions.
• Company 2 - 33% below our estimate - targets data centre buyers standardising on its GPU hardware and AI software stack.
• Company 3 - 40% below our estimate - scales device trade-in and refurbishment volumes as subsidies push consumers toward recommerce.

Those are three of them. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com